Pharmaceutical News and Articles

Millions of Backyard Pools Recalled After Drowning Deaths of Nine Children

MONDAY, July 21, 2025 Close to 5 million above-ground swimming pools have been recalled following the drowning deaths of nine children over two decades. The 48-

FDA Elevates Dubai Chocolate Spread Recall to Class 1 Over Salmonella Risk

MONDAY, July 21, 2025 The U.S. Food and Drug Administration (FDA) has escalated the recall of a popular Dubai chocolate spread sold nationwide to its highest al

Cannabis Use Disorder May Up Risk of Benign Salivary Gland Tumors

Cannabis use disorder (CUD) is associated with increased risk of benign salivary gland tumors, according to a research letter published online July 17 in JAMA O

Johnson & Johnson Seeks First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Male Virility Affected By Minimal Rises In Blood Sugar, Study Says

MONDAY, July 21, 2025 Even small increases in blood sugar might put a dent in a man s virility, a new study says. Minimally elevated blood glucose levels are li

Slower Arm Movement Increases Fall Risk Among Seniors

MONDAY, July 21, 2025 Seniors might be more prone to bone-breaking falls because they are unable to react quickly enough to regain their balance, a new study sa

Increasing Walk Cadence Counters Frailty Among Seniors, Study Says

MONDAY, July 21, 2025 Putting a little more pep in the step could help elderly folks improve their health and remain independent, a new study says. Older adults

Eggs Guilt-Free For 'Bad' Cholesterol, Experiment Shows

MONDAY, July 21, 2025 A new egg study has produced sunny-side-up results for the oft-maligned breakfast staple. Eggs are commonly thought to increase risk of he

GI Cancers On The Rise Among Younger Adults

MONDAY, July 21, 2025 GI cancers among people 50 and younger are rising at an alarming rate, increasing in the U.S. faster than any other type of early onset ca

Johnson & Johnson Receives U.S. FDA Priority Review for TAR-200 NDA in High-Risk Non-Muscle Invasive Bladder Cancer

RARITAN, N.J., JULY 17, 2025 Johnson Johnson (NYSE JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug